Mallinckrodt — Merger or Acquisition (March 2015)
8 slides from Mallinckrodt's merger presentation, Mar 5, 2015
Slide 1: Mallinckrodt Strategic Agreement Ikaria, Inc.
Exhibit 99.2 Mallinckrodt Strategic Agreement Ikaria, Inc. March 5, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements in this document that are not strictly historical, including statements regarding, the proposed acquisition of Ikaria, Inc., the expected timetable for completing the transaction, future financial condition and operating results, economic, business, competitive
Slide 3: Forward-Looking Statements (continued)
Forward-Looking Statements (continued) Mallinckrodt’s reliance on certain individual products that are material to its financial performance; Cost containment efforts of customers, purchasing groups, third-party payers and governmental organizations; The reimbursement practices of a small number of
Slide 4: Mallinckrodt expands hospital platform with Ikaria, Inc.
Mallinckrodt expands hospital platform with Ikaria, Inc. $2.3 billion agreement to fully acquire Ikaria, Inc. Diversifies portfolio with durable, high-value, branded asset Builds reputation, reach and impact of Mallinckrodt and INOmax® (Inhaled Nitric Oxide) in hospitals: 1 Extends footprint to resp
Slide 5: Transaction highlights
Transaction highlights Consideration Acquisition of Ikaria, Inc. for approximately $2.3 billion Transaction expected to add at least $150 million in net sales Financial and be accretive to Mallinckrodt’s fiscal year 2015 adjusted Impact diluted earnings per share by at least $0.25 per share 1 Struct
Slide 6: Ikaria, Inc. – growth opportunity in hospital critical care
Ikaria, Inc. – growth opportunity in hospital critical care Innovative, integrated drug/device/service Global Revenue 1 offerings to support critically ill infants in NICUs Steady growth driven by U.S. market Multi-year contracts and TotalCare ™ service foster deep relationships in ICUs INOmax/INOma
Slide 7: Integrated INOmax drug/device/service package is core to success
Integrated INOmax drug/device/service package is core to success INOmax delivery INOmax drug system Regular preventative Ongoing Highly COG service & maintenance Satisfied physician/clinician (QA/QC) Customer training Extensive distribution, 24/7/365 technical & including emergency 55 regional regio
Slide 8: Transaction continues to deliver on strategy, builds value
Transaction continues to deliver on strategy, builds value Immediately accretive to fiscal year 2015 Value creation Diversifies Mallinckrodt revenue and operating income with sustainable, growing, highly profitable business Adds innovative, difficult-to-replicate asset to Mallinckrodt portfolio Exte